



## MEDIA RELEASE

Baar, Switzerland, November 20, 2025  
medmix' Drug Delivery ("Haselmeier") highlights self-injection PiccoJect™ platform  
as innovation for high-viscosity drugs  
Page 1 of 2

medmix AG  
Neuhofstrasse 20  
CH-6340 Baar

[communications@medmix.com](mailto:communications@medmix.com)  
[www.medmix.swiss](http://www.medmix.swiss)

## MEDIA RELEASE

Baar, Switzerland, November 20, 2025

### **medmix' Drug Delivery ("Haselmeier") highlights self-injection PiccoJect™ platform as innovation for high-viscosity drugs**

medmix' Drug Delivery ("Haselmeier") showcased the proven innovation behind its PiccoJect™ platform for high-viscosity drugs at the international conferences PDA Universe in Vienna and PODD in Boston.

PiccoJect™ features a novel parallel spring mechanism that enables the delivery of both high- and low-viscosity formulations from a single, compact platform. This innovative design allows for precise and reliable adjustment of injection force, accommodating a broad range of drug viscosities while ensuring patient comfort and device reliability. The parallel spring layout also results in a rectangular cross section, which human factors studies have demonstrated to be more comfortable for users. Additionally, the design enables a large wraparound viewing window that allows patients to perform visual drug inspection and monitor injection progress with greater ease. PiccoJect™ is compatible with any standard 1 mL long or 2.25 mL prefilled syringe, enabling pharmaceutical companies to implement the device without requiring modifications to their existing filling operations.

*"The self-injection devices market is experiencing rapid expansion, which is driving pharmaceutical companies to find new ways to deliver increasingly complex drugs in patient-friendly formats," said Dr. Oliver Haferbeck, Head of Business Unit Drug Delivery, "By developing breakthrough solutions like PiccoJect™, we are strengthening medmix' position in high-growth healthcare markets and delivering the innovation our pharmaceutical partners need to bring successful therapies to patients."*



**MEDIA RELEASE**

Baar, Switzerland, November 20, 2025  
medmix' Drug Delivery ("Haselmeier") highlights self-injection PiccoJect™ platform  
as innovation for high-viscosity drugs  
Page 2 of 2

Since its introduction, PiccoJect™ has received international design awards for its ergonomic shape and innovative design. The device's simple construction of only eight parts, made with durable unfilled and bio-based polymers support efficient manufacturing and sustainability efforts. Pharmaceutical companies and industry experts value the distinct advantages the product platform provides in combination with medmix Drug Delivery expertise.

-Ends-

**About medmix**

*medmix is a global leader in high-precision delivery devices, with leading positions in healthcare, consumer and industrial end-markets. Our customers benefit from our dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2'700 employees are at service of our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). [www.medmix.swiss](http://www.medmix.swiss)*

**Inquiries:**

Media Relations: [communications@medmix.com](mailto:communications@medmix.com)

Investor Relations: [investorrelations@medmix.com](mailto:investorrelations@medmix.com)

*This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.*